Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest macular hole Stories

2013-08-16 12:24:21

-- JETREA(TM) injection represents a breakthrough for patients with symptomatic vitreomacular adhesion, a progressive eye condition often responsible for retinal distortion, vision deterioration, and irreversible damage and loss of vision1,2,3,4,5,6 -- One-time intravitreal injection of JETREA(TM) has shown efficacy in resolution of vitreomacular adhesion, compared to placebo at day 281,2...

2013-08-02 04:20:37

LEUVEN, Belgium, August 2, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA(R) (ocriplasmin) demonstrates major / significant added value in VMT patients with mild / moderately severe symptoms compared with existing comparative treatment, when...

2013-06-12 00:20:39

LEUVEN, Belgium, June 12, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has provisionally recommended JETREA(R) (ocriplasmin) for reimbursement within the National Health Service (NHS). The NICE Appraisal Consultation Document (ACD) initially recommends JETREA(R) as an option...

2013-05-27 12:20:49

LEUVEN, Belgium, May 27, 2013 /PRNewswire/ -- Roll out in Finland and Norway to follow shortly ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R) in Denmark and Sweden, the third and fourth European markets where the product is now available. Alcon will roll out the drug in Finland and...

2013-05-02 04:21:38

LEUVEN, Belgium, May 2, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R)in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA(R)is listed in the "Lauer-Taxe" (Grosse Deutsche Spezialitatentaxe) with an ex-factory price of EUR3,078....

2013-04-11 12:30:52

LEUVEN, Belgium, April 11, 2013 /PRNewswire/ -- First EU JETREA(R) order triggers EUR45 million milestone payment from Alcon to ThromboGenics ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today announces that its partner Alcon has launched JETREA(R) (ocriplasmin) in the UK, its first market in Europe. The...

2013-03-15 08:27:20

LEUVEN, Belgium, March 15, 2013 /PRNewswire/ -- EU approval of JETREA(R)triggers a EUR45 million milestone payment from Alcon ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the European Commission has approved JETREA(R) (ocriplasmin) in the European Union. JETREA(R) is approved for the...

2013-02-06 23:03:43

The Retina Group of New York (RGONY) with offices in Hicksville and Hauppauge, NY, has announced the availability of JETREA® (Ocriplasmin), the first non-surgical treatment for patients with symptomatic Vitreo-macular Adhesion (VMA) or Vitreo-macular Traction (VMT). Hicksville and Hauppauge, NY (PRWEB) February 06, 2013 The Retina Group of New York (RGONY) with offices in Hicksville and Hauppauge, NY, has announced the availability of JETREA® (Ocriplasmin), the first non-surgical...

2013-01-18 08:23:22

LEUVEN, Belgium, January 18, 2013 /PRNewswire/ -- Positive opinion clears the way for the potential EMA approval of JETREA(R)as the first pharmacological option for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and...

2012-03-08 10:40:00

LEUVEN, Belgium, March 8, 2012 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today issued a business update and its financial results for the full year ending December 31, 2011. Over the past 12 months, ThromboGenics has built its capabilities in anticipation of the launch of its lead product, ocriplasmin. It has filed a regulatory submission in Europe for ocriplasmin for...